AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. SLNO
  4. [Form 4] Soleno Therapeutics, Inc. Insider Trading Activity

[Form 4] Soleno Therapeutics, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Soleno Therapeutics insider Patricia C. Hirano, Senior Vice President of Regulatory Affairs, executed a planned transaction under Rule 10b5-1 on June 24, 2025. The transaction involved:

  • Exercise of employee stock options for 266 shares at $44.25 per share
  • Immediate sale of the acquired 266 shares at $84.25 per share
  • Net gain of $40 per share on the transaction

Following the transactions, Hirano holds 17,036 shares directly, some in the form of restricted stock units (RSUs). Notable adjustments include a 10,000-share reduction from an internal holdings review. The transactions were executed according to a trading plan established on September 13, 2024, demonstrating compliance with insider trading regulations.

Patricia C. Hirano, Senior Vice President degli Affari Regolatori di Soleno Therapeutics, ha eseguito una transazione programmata secondo la Regola 10b5-1 il 24 giugno 2025. La transazione ha comportato:

  • Esercizio di opzioni azionarie per dipendenti per 266 azioni al prezzo di 44,25$ per azione
  • Vendita immediata delle 266 azioni acquisite a 84,25$ per azione
  • Guadagno netto di 40$ per azione dalla transazione

Dopo le transazioni, Hirano detiene direttamente 17.036 azioni, alcune sotto forma di Restricted Stock Units (RSU). Tra le modifiche rilevanti si segnala una riduzione di 10.000 azioni a seguito di una revisione interna delle partecipazioni. Le operazioni sono state eseguite in conformit脿 a un piano di trading stabilito il 13 settembre 2024, dimostrando il rispetto delle normative sul trading degli insider.

Patricia C. Hirano, Vicepresidenta Senior de Asuntos Regulatorios de Soleno Therapeutics, realiz贸 una transacci贸n planificada bajo la Regla 10b5-1 el 24 de junio de 2025. La transacci贸n incluy贸:

  • Ejercicio de opciones sobre acciones para empleados por 266 acciones a 44,25$ por acci贸n
  • Venta inmediata de las 266 acciones adquiridas a 84,25$ por acci贸n
  • Ganancia neta de 40$ por acci贸n en la transacci贸n

Tras las transacciones, Hirano posee directamente 17.036 acciones, algunas en forma de unidades de acciones restringidas (RSU). Entre los ajustes destacados se incluye una reducci贸n de 10.000 acciones tras una revisi贸n interna de participaciones. Las transacciones se ejecutaron conforme a un plan de trading establecido el 13 de septiembre de 2024, demostrando cumplimiento con las regulaciones sobre operaciones con informaci贸n privilegiada.

靻旊爤雲� 韰岆澕頁嫳鞀�鞚� 雮措秬鞛愳澊鞛� 攴滌牅雼措嫻 靾橃劃 攵�靷灔鞚� 韺姼毽儰 C. 頌堧澕雲�臧� 2025雲� 6鞗� 24鞚� 攴滌箼 10b5-1鞐� 霐半ジ 瓿勴殟霅� 瓯半灅毳� 鞁ろ枆頄堨姷雼堧嫟. 瓯半灅 雮挫毄鞚� 雼れ潓瓿� 臧欖姷雼堧嫟:

  • 歆侅洂 鞀ろ啞鞓奠厴 266欤茧ゼ 欤茧嫻 44.25雼煬鞐� 頄夓偓
  • 旆摑頃� 266欤茧ゼ 歃夓嫓 欤茧嫻 84.25雼煬鞐� 毵る弰
  • 瓯半灅雼� 欤茧嫻 40雼煬鞚� 靾滌澊鞚� 氚滌儩

瓯半灅 頉� 頌堧澕雲鸽姅 鞝滍暅 欤检嫕 雼渼(RSU) 順曧儨毳� 韽暔頃� 歆侅爲 17,036欤�毳� 氤挫湢頃橁碃 鞛堨姷雼堧嫟. 雮措秬 氤挫湢 瓴�韱� 瓴瓣臣 10,000欤缄皜 臧愳唽頃� 鞝愳澊 欤茧霅╇媹雼�. 鞚� 瓯半灅霌れ潃 2024雲� 9鞗� 13鞚检棎 靾橂霅� 瓯半灅 瓿勴殟鞐� 霐半澕 鞁ろ枆霅橃柎 雮措秬鞛� 瓯半灅 攴滌爼鞚� 欷�靾橅暔鞚� 氤挫棳欷嶋媹雼�.

Patricia C. Hirano, Vice-Pr茅sidente Senior des Affaires R茅glementaires chez Soleno Therapeutics, a r茅alis茅 une transaction planifi茅e conform茅ment 脿 la r猫gle 10b5-1 le 24 juin 2025. La transaction comprenait :

  • Exercice d鈥檕ptions d鈥檃chat d鈥檃ctions pour employ茅s portant sur 266 actions au prix de 44,25$ par action
  • Vente imm茅diate des 266 actions acquises 脿 84,25$ par action
  • Gain net de 40$ par action sur la transaction

脌 la suite de ces op茅rations, Hirano d茅tient directement 17 036 actions, certaines sous forme d鈥檜nit茅s d鈥檃ctions restreintes (RSU). Parmi les ajustements notables figure une r茅duction de 10 000 actions suite 脿 une revue interne des avoirs. Les transactions ont 茅t茅 ex茅cut茅es selon un plan de trading 茅tabli le 13 septembre 2024, d茅montrant le respect des r猫gles relatives aux op茅rations d鈥檌niti茅s.

Patricia C. Hirano, Senior Vice President f眉r Regulatory Affairs bei Soleno Therapeutics, f眉hrte am 24. Juni 2025 eine geplante Transaktion gem盲脽 Regel 10b5-1 durch. Die Transaktion umfasste:

  • Aus眉bung von Mitarbeiteraktienoptionen f眉r 266 Aktien zum Preis von 44,25$ pro Aktie
  • Unmittelbarer Verkauf der erworbenen 266 Aktien zu je 84,25$
  • Nettoertrag von 40$ pro Aktie aus der Transaktion

Nach den Transaktionen h盲lt Hirano direkt 17.036 Aktien, teilweise in Form von Restricted Stock Units (RSUs). Bemerkenswerte Anpassungen beinhalten eine Reduzierung um 10.000 Aktien nach einer internen Bestandspr眉fung. Die Transaktionen wurden gem盲脽 einem am 13. September 2024 festgelegten Handelsplan ausgef眉hrt, was die Einhaltung der Insiderhandelsvorschriften belegt.

Positive
  • None.
Negative
  • None.

Patricia C. Hirano, Senior Vice President degli Affari Regolatori di Soleno Therapeutics, ha eseguito una transazione programmata secondo la Regola 10b5-1 il 24 giugno 2025. La transazione ha comportato:

  • Esercizio di opzioni azionarie per dipendenti per 266 azioni al prezzo di 44,25$ per azione
  • Vendita immediata delle 266 azioni acquisite a 84,25$ per azione
  • Guadagno netto di 40$ per azione dalla transazione

Dopo le transazioni, Hirano detiene direttamente 17.036 azioni, alcune sotto forma di Restricted Stock Units (RSU). Tra le modifiche rilevanti si segnala una riduzione di 10.000 azioni a seguito di una revisione interna delle partecipazioni. Le operazioni sono state eseguite in conformit脿 a un piano di trading stabilito il 13 settembre 2024, dimostrando il rispetto delle normative sul trading degli insider.

Patricia C. Hirano, Vicepresidenta Senior de Asuntos Regulatorios de Soleno Therapeutics, realiz贸 una transacci贸n planificada bajo la Regla 10b5-1 el 24 de junio de 2025. La transacci贸n incluy贸:

  • Ejercicio de opciones sobre acciones para empleados por 266 acciones a 44,25$ por acci贸n
  • Venta inmediata de las 266 acciones adquiridas a 84,25$ por acci贸n
  • Ganancia neta de 40$ por acci贸n en la transacci贸n

Tras las transacciones, Hirano posee directamente 17.036 acciones, algunas en forma de unidades de acciones restringidas (RSU). Entre los ajustes destacados se incluye una reducci贸n de 10.000 acciones tras una revisi贸n interna de participaciones. Las transacciones se ejecutaron conforme a un plan de trading establecido el 13 de septiembre de 2024, demostrando cumplimiento con las regulaciones sobre operaciones con informaci贸n privilegiada.

靻旊爤雲� 韰岆澕頁嫳鞀�鞚� 雮措秬鞛愳澊鞛� 攴滌牅雼措嫻 靾橃劃 攵�靷灔鞚� 韺姼毽儰 C. 頌堧澕雲�臧� 2025雲� 6鞗� 24鞚� 攴滌箼 10b5-1鞐� 霐半ジ 瓿勴殟霅� 瓯半灅毳� 鞁ろ枆頄堨姷雼堧嫟. 瓯半灅 雮挫毄鞚� 雼れ潓瓿� 臧欖姷雼堧嫟:

  • 歆侅洂 鞀ろ啞鞓奠厴 266欤茧ゼ 欤茧嫻 44.25雼煬鞐� 頄夓偓
  • 旆摑頃� 266欤茧ゼ 歃夓嫓 欤茧嫻 84.25雼煬鞐� 毵る弰
  • 瓯半灅雼� 欤茧嫻 40雼煬鞚� 靾滌澊鞚� 氚滌儩

瓯半灅 頉� 頌堧澕雲鸽姅 鞝滍暅 欤检嫕 雼渼(RSU) 順曧儨毳� 韽暔頃� 歆侅爲 17,036欤�毳� 氤挫湢頃橁碃 鞛堨姷雼堧嫟. 雮措秬 氤挫湢 瓴�韱� 瓴瓣臣 10,000欤缄皜 臧愳唽頃� 鞝愳澊 欤茧霅╇媹雼�. 鞚� 瓯半灅霌れ潃 2024雲� 9鞗� 13鞚检棎 靾橂霅� 瓯半灅 瓿勴殟鞐� 霐半澕 鞁ろ枆霅橃柎 雮措秬鞛� 瓯半灅 攴滌爼鞚� 欷�靾橅暔鞚� 氤挫棳欷嶋媹雼�.

Patricia C. Hirano, Vice-Pr茅sidente Senior des Affaires R茅glementaires chez Soleno Therapeutics, a r茅alis茅 une transaction planifi茅e conform茅ment 脿 la r猫gle 10b5-1 le 24 juin 2025. La transaction comprenait :

  • Exercice d鈥檕ptions d鈥檃chat d鈥檃ctions pour employ茅s portant sur 266 actions au prix de 44,25$ par action
  • Vente imm茅diate des 266 actions acquises 脿 84,25$ par action
  • Gain net de 40$ par action sur la transaction

脌 la suite de ces op茅rations, Hirano d茅tient directement 17 036 actions, certaines sous forme d鈥檜nit茅s d鈥檃ctions restreintes (RSU). Parmi les ajustements notables figure une r茅duction de 10 000 actions suite 脿 une revue interne des avoirs. Les transactions ont 茅t茅 ex茅cut茅es selon un plan de trading 茅tabli le 13 septembre 2024, d茅montrant le respect des r猫gles relatives aux op茅rations d鈥檌niti茅s.

Patricia C. Hirano, Senior Vice President f眉r Regulatory Affairs bei Soleno Therapeutics, f眉hrte am 24. Juni 2025 eine geplante Transaktion gem盲脽 Regel 10b5-1 durch. Die Transaktion umfasste:

  • Aus眉bung von Mitarbeiteraktienoptionen f眉r 266 Aktien zum Preis von 44,25$ pro Aktie
  • Unmittelbarer Verkauf der erworbenen 266 Aktien zu je 84,25$
  • Nettoertrag von 40$ pro Aktie aus der Transaktion

Nach den Transaktionen h盲lt Hirano direkt 17.036 Aktien, teilweise in Form von Restricted Stock Units (RSUs). Bemerkenswerte Anpassungen beinhalten eine Reduzierung um 10.000 Aktien nach einer internen Bestandspr眉fung. Die Transaktionen wurden gem盲脽 einem am 13. September 2024 festgelegten Handelsplan ausgef眉hrt, was die Einhaltung der Insiderhandelsvorschriften belegt.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Hirano Patricia C
(Last) (First) (Middle)
100 MARINE PARKWAY, SUITE 400
(Street)
REDWOOD CITY CA 94065
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
SOLENO THERAPEUTICS INC [ SLNO ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
SEE REMARKS
3. Date of Earliest Transaction (Month/Day/Year)
06/24/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/24/2025 M(1) 266 A $44.25 17,302(2)(3) D
Common Stock 06/24/2025 S(1) 266 D $84.25 17,036(2) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Employee stock option (right to buy) $44.25 06/24/2025 M(1) 266 (4) 04/19/2027 Common Stock 266 $0 0 D
Explanation of Responses:
1. The option exercise and sale were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person September 13, 2024
2. Certain of these securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
3. The number of shares beneficially owned has been decreased by 10,000 shares pursuant to an internal review of the Reporting Person's holdings.
4. All of the shares subject to this option are fully vested and exercisable as of the date hereof.
Remarks:
Officer title: Senior Vice President, Regulatory Affairs
/s/ Anish Bhatnagar, Attorney-in-Fact 06/26/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

What insider trading activity occurred at SLNO on June 24, 2025?

Patricia C. Hirano, Senior Vice President of Regulatory Affairs at SLNO, exercised 266 stock options at $44.25 per share and immediately sold those 266 shares at $84.25 per share. This transaction was executed according to a Rule 10b5-1 trading plan established on September 13, 2024.

How many shares does Patricia Hirano own in SLNO after the reported transaction?

Following the reported transactions, Patricia Hirano beneficially owns 17,036 shares of SLNO directly. Some of these shares are in the form of restricted stock units (RSUs), each representing a contingent right to receive one share of Common Stock.

What was the profit from SLNO insider's stock option exercise on June 24, 2025?

The insider made a profit of $40 per share ($84.25 sale price - $44.25 exercise price = $40) on 266 shares, resulting in a total profit of $10,640 before taxes and fees from the options exercise and sale transaction.

Was SLNO insider Patricia Hirano's trade pre-planned?

Yes, the trade was pre-planned. The Form 4 indicates that both the option exercise and sale were executed pursuant to a Rule 10b5-1 trading plan that Patricia Hirano adopted on September 13, 2024.

What is Patricia Hirano's position at SLNO?

Patricia C. Hirano serves as Senior Vice President of Regulatory Affairs at Soleno Therapeutics Inc (SLNO).
Stock SLNO logo
Soleno Therapeutics Inc

NASDAQ:SLNO

SLNO Rankings

#2710 Ranked by Market Cap
N/A Ranked by Dividends

SLNO Latest News

Jul 10, 2025
Soleno Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock
Jul 10, 2025
Soleno Therapeutics Announces Proposed $200 Million Public Offering of Common Stock
Jul 10, 2025
Soleno Therapeutics Announces Preliminary Financial and Operational Results for the Second Quarter Ended June 30, 2025
Jul 1, 2025
Soleno Therapeutics Announces Two Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ENDO 2025
Jun 25, 2025
Soleno Therapeutics Highlights New Data on VYKAT(TM) XR at the 2025 United in Hope: International Prader-Willi Syndrome Conference

SLNO Latest SEC Filings

Jul 10, 2025
[8-K] Soleno Therapeutics, Inc. Reports Material Event
Jul 10, 2025
[424B5] Soleno Therapeutics, Inc. Prospectus Supplement (Debt Securities)
Jul 3, 2025
[Form 4] Soleno Therapeutics, Inc. Insider Trading Activity
Jul 1, 2025
[144] Soleno Therapeutics, Inc. SEC Filing
Jun 24, 2025
[144] Soleno Therapeutics, Inc. SEC Filing

SLNO Stock Data

4.34B
47.40M
2.93%
113.72%
10.48%
Biotechnology
Electromedical & Electrotherapeutic Apparatus
United States
REDWOOD CITY